Psychedeli Competitors

We are Compass, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. We believe people living with mental health conditions deserve the possibility of a better future. Our initial focus is advancing COMP360, a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability, with infrequent dosing. We’re driven by our purpose of unlocking pathways to be—opening futures filled with possibility. Together, we’re on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery. Every journey needs a Compass.

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. We further our mission by: ● Developing psychedelics and marijuana into prescription medicines ● Training therapists and working to establish a network of treatment centers ● Supporting scientific research into spirituality, creativity, and neuroscience ● Educating the public honestly about the risks and benefits of psychedelics and marijuana

Fluence is the leading provider of psychedelic therapy education, serving both individual clinicians and organizations developing psychedelic therapeutics. For practitioners, Fluence offers professional certificate programs in Ketamine-Assisted Psychotherapy, Psychedelic Harm Reduction and Integration, and Psilocybin Facilitation for licensed clinicians, alongside on-demand courses open to anyone interested in learning more about the field. For drug developers and clinical research organizations, Fluence provides end-to-end trial support: protocol consultation, treatment manual development, therapist training, AI-assisted adherence feedback, post-approval commercialization planning, and proprietary software built for the clinical trials regulated environment. Fluence has supported more than a dozen drug developers across multiple compounds and multinational studies.